Acute myeloid leukemia (AML) with t (8; 21)(q22; q22. 1); RUNX1-RUNX1T1, one of the core-
binding factor leukemias, is one of the most common subtypes of AML with recurrent genetic …

Abstract The chromosomal translocation t (8; 21) and the resulting oncofusion gene
AML1/ETO have long served as a prototypical genetic lesion to model and understand …

Several canonical translocations produce oncofusion genes that can initiate acute myeloid
leukemia (AML). Although each translocation is associated with unique features, the …

Core binding factor acute myeloid leukemia (CBF AML), defined by t (8; 21) or inv (16), is a
subset of favorable risk AML. Despite its association with a high complete remission rate …

The runt-related transcription factors (RUNX) play prominent roles in cell cycle progression,
differentiation, apoptosis, immunity and epithelial–mesenchymal transition. There are three …

Introduction: RUNX1 is an essential transcription factor for normal and malignant
hematopoiesis. RUNX1 forms a heterodimeric complex with CBFB. Germline mutations and …

Dissecting and identifying the major actors and pathways in the genesis, progression and
aggressive advancement of breast cancer is challenging, in part because neoplasms arising …

Understanding the molecular pathogenesis of acute myeloid leukemia (AML) with well-
defined genomic abnormalities has facilitated the development of targeted therapeutics …

Simple Summary The advent of DNA massive sequencing technologies has allowed for the
first time an extensive look into the heterogeneous spectrum of genes and mutations …

Summary The ETV6-RUNX1 onco-fusion arises in utero, initiating a clinically silent pre-
leukemic state associated with the development of pediatric B-acute lymphoblastic leukemia …